BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search
 Company Profile

 

Selexys Pharmaceuticals Corporation 

800 Research Parkway
Suite 338
Oklahoma City  Oklahoma  73104  U.S.A.
Phone: 405-319-8195 Fax: 405-319-8197


SEARCH JOBS




Industry
Pharmaceutical






 Company News
Cytovance Biologics Inc. And Selexys Pharmaceuticals Corporation Announce Development And cGMP Manufacturing Agreement For SELK2 Drug Product 5/6/2014 9:34:50 AM
Selexys Pharmaceuticals Corporation Initiates SUSTAIN Phase 2 Clinical Trial in Sickle Cell Patients With Pain Crises 8/19/2013 11:06:43 AM
Cytovance Biologics Inc. Announces Manufacturing Agreement With Selexys Pharmaceuticals Corporation for Phase II Production of SelG1 11/14/2012 11:17:02 AM
Selexys Pharmaceuticals Corporation Completes $23 Million Equity Financing and Signs Agreement With Novartis Pharmaceuticals Corporation (NVS) for Up to $665 Million 9/19/2012 7:29:31 AM
Selexys Pharmaceuticals Corporation Completes Phase I Clinical Study for Sickle Cell Drug 12/19/2011 10:51:47 AM
Selexys Pharmaceuticals Corporation Initiates Enrollment in Phase I Clinical Study of SelG1 5/4/2011 10:41:28 AM
Cytovance Biologics Awarded Biopharmaceutical Development and Manufacturing Contract by Selexys Pharmaceuticals Corporation 4/26/2010 10:04:38 AM
Selexys Pharmaceuticals Corporation and Cytovance Biologics Sign Deal for the Process Development and cGMP Manufacture of Selexys Pharmaceutical Corporation’s Product HPL1 Monoclonal Antibody (Mab) 1/26/2009 9:57:57 AM
Selexys Pharmaceuticals Corporation Selects Cytovance Biologics for Process Development Services to Accelerate Development Programs 8/1/2007 10:27:49 AM